Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators.
Infant immunization is a particularly important field with multiple challenges for vaccine research and development. There is, together with a high susceptibility to infections, a lower efficacy of most vaccinations in newborns and young infants, compared to those performed later in life. In the present review, the authors focus on problems arising from the attempt to vaccinate against pathogens very early in life, and on the role of selective adjuvants (i.e. antigen delivery systems or immunomodulators) that could be used to: (i) rapidly induce strong antibody responses of the appropriate isotypes; (ii) elicit sustained antibody responses extending beyond infancy; (iii) induce efficient Th1 and CTL responses in spite of the preferential Th2 polarization of early life responses; (iv) escape from maternal antibody mediated inhibition of vaccine responses; (v) show acceptable reactogenicity in early life; and (vi) allow incorporation of several vaccine antigens into a single formulation so as to reduce the number of required injections. How such objectives might be achieved by several of the vaccine formulations currently in development is illustrated by reviewing data from experimental models and clinical studies, when available.
World Health Organization Collaborating Centre for Neonatal Vaccinology, Department of Pathology, University of Geneva, Switzerland. jiri.kovarik@medecine.unige.ch
J
J
Kovarik
C A
CA
Siegrist
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D006801:Humans; D007231:Infant, Newborn; D014611:Vaccination / Q000379:methods* / Q000639:trends; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D014765:Viral Vaccines